Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1960 1
1969 1
1972 2
1979 3
1981 2
1986 1
1990 1
1994 3
1995 2
1996 2
1997 1
1998 2
1999 2
2001 2
2002 1
2003 3
2004 1
2005 3
2006 1
2007 3
2008 2
2009 2
2010 3
2011 3
2012 1
2013 2
2015 7
2016 5
2017 4
2018 7
2019 5
2020 8
2021 10
2022 15
2023 23
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C.
Bremova-Ertl T, Ramaswami U, Brands M, Foltan T, Gautschi M, Gissen P, Gowing F, Hahn A, Jones S, Kay R, Kolnikova M, Arash-Kaps L, Marquardt T, Mengel E, Park JH, Reichmannová S, Schneider SA, Sivananthan S, Walterfang M, Wibawa P, Strupp M, Martakis K. Bremova-Ertl T, et al. N Engl J Med. 2024 Feb 1;390(5):421-431. doi: 10.1056/NEJMoa2310151. N Engl J Med. 2024. PMID: 38294974 Clinical Trial.
BACKGROUND: Niemann-Pick disease type C is a rare lysosomal storage disorder. We evaluated the safety and efficacy of N-acetyl-l-leucine (NALL), an agent that potentially ameliorates lysosomal and metabolic dysfunction, for the treatment of Niemann-Pic …
BACKGROUND: Niemann-Pick disease type C is a rare lysosomal storage disorder. We evaluated the safety and efficacy of N-acetyl …
Drug treatment.
Perlman S, Boltshauser E. Perlman S, et al. Handb Clin Neurol. 2018;155:371-377. doi: 10.1016/B978-0-444-64189-2.00024-X. Handb Clin Neurol. 2018. PMID: 29891072 Review.
Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses.
Martakis K, Claassen J, Gascon-Bayari J, Goldschagg N, Hahn A, Hassan A, Hennig A, Jones S, Kay R, Lau H, Perlman S, Sharma R, Schneider S, Bremova-Ertl T. Martakis K, et al. Neurology. 2023 Mar 7;100(10):e1072-e1083. doi: 10.1212/WNL.0000000000201660. Epub 2022 Dec 1. Neurology. 2023. PMID: 36456200 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) are rare, autosomal recessive, neurodegenerative diseases with no available symptomatic or disease-modifying treatments. This clinical trial investigated N-acetyl-l-leucine …
BACKGROUND AND OBJECTIVES: GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) are rare, autosomal recessive, neurodegenerative diseases wi …
Pharmacotherapy of cerebellar and vestibular disorders.
Lemos J, Manto M. Lemos J, et al. Curr Opin Neurol. 2022 Feb 1;35(1):118-125. doi: 10.1097/WCO.0000000000001015. Curr Opin Neurol. 2022. PMID: 34845147 Review.
RECENT FINDINGS: Recently, the use of omaveloxolone for 2 years significantly improved upright stability in Friedreich's ataxia patients. In an open-label study, N-acetyl-l-leucine administered for 6-weeks significantly improved clinical impression of …
RECENT FINDINGS: Recently, the use of omaveloxolone for 2 years significantly improved upright stability in Friedreich's ataxia patients. In …
N-acetyl-L-leucine protects MPTP-treated Parkinson's disease mouse models by suppressing Desulfobacterota via the gut-brain axis.
Xu Z, Lian C, Pan L, Lai W, Zhang F, Peng L, Zhou S, Zhao G, Yang X, Zhang G, Tan Z, Wang Y. Xu Z, et al. Brain Res Bull. 2023 Oct 1;202:110729. doi: 10.1016/j.brainresbull.2023.110729. Epub 2023 Aug 12. Brain Res Bull. 2023. PMID: 37579888 Free article.
Moreover, Pearson correlation analysis suggested that the protective factor N-acetyl-L-leucine (NALL) may be associated with neuroinflammation in the striatum and substantia nigra, which also had a negative relationship with the concentration of Desulf …
Moreover, Pearson correlation analysis suggested that the protective factor N-acetyl-L-leucine (NALL) may be ass …
N-Acetyl-l-Leucine-Polyethyleneimine-Mediated Delivery of CpG Oligodeoxynucleotides 2006 Inhibits RAW264.7 Cell Osteoclastogenesis.
Wang H, Yu W, Li H, Zheng Y, Chen Z, Lin H, Shen Y. Wang H, et al. Drug Des Devel Ther. 2020 Jul 7;14:2657-2665. doi: 10.2147/DDDT.S241826. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32764870 Free PMC article.
However, the inherent instability and rapid degradation hinder their wider application. This study aimed to evaluate whether N-acetyl-L-leucine-modified polyethyleneimine (N-Ac-L-Leu-PEI) could effectively deliver CpG ODN 2006 to RAW264.7 cells and and …
However, the inherent instability and rapid degradation hinder their wider application. This study aimed to evaluate whether N-ace …
Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C.
Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K, Raethjen J, Ramaswami U, Sharma R, Schneider SA. Bremova-Ertl T, et al. J Neurol. 2022 Mar;269(3):1651-1662. doi: 10.1007/s00415-021-10717-0. Epub 2021 Aug 13. J Neurol. 2022. PMID: 34387740 Free PMC article. Clinical Trial.
OBJECTIVE: To investigate the safety and efficacy of N-acetyl-L-leucine (NALL) on symptoms, functioning, and quality of life in pediatric ( 6 years) and adult Niemann-Pick disease type C (NPC) patients. ...
OBJECTIVE: To investigate the safety and efficacy of N-acetyl-L-leucine (NALL) on symptoms, functioning, and qua …
A Novel Modified Lipid: Enzymatic Esterification of 2-Monoacylglycerol with N-acetyl-l-leucine.
Keskin Çavdar H, Koçak Yanık D, Göğüş F, Fadıloğlu S. Keskin Çavdar H, et al. J Food Sci. 2018 Mar;83(3):597-604. doi: 10.1111/1750-3841.14070. Epub 2018 Feb 13. J Food Sci. 2018. PMID: 29437236
The objective of this research was to synthesize and characterize a novel modified lipid which is composed of mainly oleic acid at sn-2 position and a hydrophobic essential amino acid derivative (N-acetyl-l-leucine) at sn-1(3) or sn-1, 3 positions. LC- …
The objective of this research was to synthesize and characterize a novel modified lipid which is composed of mainly oleic acid at sn-2 posi …
123 results